|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Friday, October 20, 2006
Biogen gets FDA OK for longer storage of Avonex -
Cambridge's Biogen Idec reports the U.S. Food and Drug Administration has approved storage of its multiple sclerosis treatment Avonex for up to seven days at room temperature. Company officials say the FDA approval is indicative of Biogen's efforts to improve treatments for people with multiple sclerosis, and it gives an added convenience to people taking Avonex. Launched in 1996, Avonex is taken by an estimated 130,000 patients and has been approved in the United States and Europe. |